Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q2 2021 · 10-Q
Revenue$11.16M$11.16M+104.8% vs Q2 2020 Net Income-$3.45M-$3.45MN/M vs Q2 2020 EPS Diluted-$0.84-$0.84N/M vs Q2 2020 Gross Profit$5,355,000+235.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,819,000N/M Margins · derivedGross margin48.0%+18.7 pt vs Q2 2020
Operating margin-26.1%+79.9 pt vs Q2 2020
Net margin-30.9%+71.6 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 11, 2021 · 42 d after period end